Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

[Research advances of anti-CD40 monoclonal antibody].

Luo LL, Zhang Y, Hou CM, Qiao CX, Li Y.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Apr;21(2):508-12. doi: 10.7534/j.issn.1009-2137.2013.02.053. Review. Chinese.

PMID:
23628065
2.

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS.

Cancer Res. 2005 Sep 15;65(18):8331-8. Erratum in: Cancer Res. 2006 Feb 15;66(4):2495.

3.

CD40 activation as potential tool in malignant neoplasms.

Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR.

Tumori. 2002 Sep-Oct;88(5):361-6. Review.

PMID:
12487551
4.

Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.

Hassan SB, Sørensen JF, Olsen BN, Pedersen AE.

Immunopharmacol Immunotoxicol. 2014 Apr;36(2):96-104. doi: 10.3109/08923973.2014.890626. Epub 2014 Feb 21. Review.

PMID:
24555495
5.

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.

Carpenter EL, Mick R, Rüter J, Vonderheide RH.

J Transl Med. 2009 Nov 11;7:93. doi: 10.1186/1479-5876-7-93.

6.

p38 mitogen-activated protein kinase and nuclear factor-κB facilitate CD40-mediated salivary epithelial cell death.

Ping L, Ogawa N, Zhang Y, Sugai S, Masaki Y, Weiguo X.

J Rheumatol. 2012 Jun;39(6):1256-64. doi: 10.3899/jrheum.110097. Epub 2012 Apr 15.

PMID:
22505709
7.

Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies.

Schwabe RF, Hess S, Johnson JP, Engelmann H.

Hybridoma. 1997 Jun;16(3):217-26.

PMID:
9219031
8.

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM.

Cancer Immunol Res. 2014 Jan;2(1):80-90. doi: 10.1158/2326-6066.CIR-13-0067. Epub 2013 Oct 21.

9.

Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.

Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP.

Thromb Haemost. 2001 Dec;86(6):1345-52.

PMID:
11776297
10.

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.

Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC.

Cancer Res. 2005 Dec 15;65(24):11712-20.

11.

Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice.

Resetkova E, Kawai K, Enomoto T, Arreaza G, Togun R, Foy TM, Noelle RJ, Volpé R.

Thyroid. 1996 Aug;6(4):267-73.

PMID:
8875745
12.

Targeting CD40 in Waldenström's macroglobulinemia.

Lee M, Advani R.

Clin Lymphoma Myeloma. 2009 Mar;9(1):87-9. doi: 10.3816/CLM.2009.n.023. Review.

PMID:
19362983
13.

Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.

Lu L, Li W, Fu F, Chambers FG, Qian S, Fung JJ, Thomson AW.

Transplantation. 1997 Dec 27;64(12):1808-15.

PMID:
9422424
14.
15.

Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis.

Tanaka H, Yang GX, Iwakoshi N, Knechtle SJ, Kawata K, Tsuneyama K, Leung P, Coppel RL, Ansari AA, Joh T, Bowlus C, Gershwin ME.

Clin Exp Immunol. 2013 Dec;174(3):364-71. doi: 10.1111/cei.12193.

16.

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.

Gladue RP, Paradis T, Cole SH, Donovan C, Nelson R, Alpert R, Gardner J, Natoli E, Elliott E, Shepard R, Bedian V.

Cancer Immunol Immunother. 2011 Jul;60(7):1009-17. doi: 10.1007/s00262-011-1014-6. Epub 2011 Apr 12.

PMID:
21479995
17.

The use of agonistic anti-CD40 therapy in treatments for cancer.

Khong A, Nelson DJ, Nowak AK, Lake RA, Robinson BW.

Int Rev Immunol. 2012 Aug;31(4):246-66. doi: 10.3109/08830185.2012.698338. Review.

PMID:
22804570
18.

Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14.

Francisco JA, Donaldson KL, Chace D, Siegall CB, Wahl AF.

Cancer Res. 2000 Jun 15;60(12):3225-31.

19.

Affinity and epitope profiling of mouse anti-CD40 monoclonal antibodies.

Malmborg Hager AC, Ellmark P, Borrebaeck CA, Furebring C.

Scand J Immunol. 2003 Jun;57(6):517-24.

Supplemental Content

Support Center